Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids
Husson MO, Ley D, Portal C, Gottrand M, Hueso T, Desseyn JL, Gottrand F
The Journal of infection · 75 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- French Foundation
Según 1 financiador declarado.
Publicación
- Publicado
- 2016-10-17 · J Infect · vol. 73 · número 6 · págs. 523–535
- Editorial
- Elsevier BV
- Citado
- 103 citas · más que el 93% de estudios similares · 4.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 121 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Immune Response and Inflammation · Edible Oils Quality and Analysis
- Palabras clave
- omega-3 polyunsaturated fatty acids, n-3 long-chain polyunsaturated fatty acids, anti-inflammatory activity, immune response, Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Citrobacter rodentium, Helicobacter hepaticus, Mycobacterium tuberculosis, Salmonella, influenza virus, herpes simplex virus, dose-dependent effects, dietary supplementation, intestinal infection, intracellular pathogens
- MeSH
- humans, citrobacter rodentium, helicobacter hepaticus, mycobacterium tuberculosis, staphylococcus aureus, bacterial infections, staphylococcal infections, virus diseases, herpes simplex, chronic disease, inflammation, fatty acids, omega-3, administration, oral, dietary supplements
7 autores
- Marie-Odile Husson🇫🇷 · autor de correspondenciaInserm; Université de Lille; Lille Inflammation Research International Center
- Delphine Ley🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
- Céline Portal🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
- Madeleine Aumar🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
- Thomas Hueso🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
- Jean‐Luc Desseyn🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
- Frédèric Gottrand🇫🇷Inserm; Université de Lille; Centre Hospitalier Universitaire de Lille; Lille Inflammation Research International Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
Although n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) are used widely in the treatment of chronic inflammatory diseases, their effect in infectious disease requires a particular attention.
Methods
The present article discusses their anti-inflammatory and immune properties involved in the host defence and presents a systematic review of the effects of their oral administration on the prevention and outcome of experimental and clinical infections.
Results
At a dose corresponding to an human dose of 500 mg/day, n-3 LC-PUFAs intake is beneficial against experimental infections caused by extracellular pathogens including Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus by reducing inflammation, and reduces the incidence of pneumococcal infections in the elderly, but at 2-4-fold higher doses as occurs in some human intervention and/or during long-term it becomes detrimental in intestinal infections with Citrobacter rodentium or Helicobacter hepaticus by exacerbating anti-inflammatory response. They are also harmful against infections caused by intracellular pathogens as Mycobacterium tuberculosis, Salmonella, Influenza virus and Herpes simplex virus by affecting the immune cell response.
Conclusion
The effects of n-3-LC-PUFAs on infections depend on the pathogen and the n-3 LC-PUFA dose and timing. Caution should be recommended for high-dose and long-term supplementation in humans.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.